Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease. Antibiotic lock therapy is considered adjunctive therapy in the treatment of CRBSI when catheter removal is not a favorable option. The current treatment options are used as off-label therapies and only a few non-antibiotic lock solutions are approved in Europe.

 

DelveInsight’s “Catheter-Related Bloodstream Infection (CRBSI) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Catheter-Related Bloodstream Infection (CRBSI), historical and forecasted epidemiology as well as the Catheter-Related Bloodstream Infection (CRBSI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

CRBSI Epidemiology Key Findings

• As per the DelveInsight’s estimates, the incident population of CRBSI in the 7MM was found to be 674,347, in 2020.
• The estimates show a higher incidence of CRBSI in the US with 330,686 cases, in 2020.
• As per the analysis, in the US, the incidence of Gram-positive bacteria is more than Gram-negative bacteria and very few are affected with candida species (fungi). Methicillin susceptible Staphylococcusaureus occupies the maximum patient pool among the Gram-positive bacteria, with 143,072 cases of this category, in 2020.
• Among EU5 countries, Germany accounted for the highest incidence of CRBSI with 62,368 cases in 2020. Whereas, the least number of cases was contributed by Spain with 16,793 cases.
• The diagnosed incident cases of CRBSI, in 2020, were found to be 648,351 in the 7MM.
• The United States accounted for the highest diagnosed incidence with 317,938 cases in 2020.
• Among EU5 countries, Germany accounted for the highest diagnosed incidence of CRBSI with 59,964 cases in 2020. Whereas, the least number of cases was contributed by Spain with 16,146 cases.

 

CRBSI Market Key Findings

• The market size of CRBSI, in the 7MM, was USD 706.3 million in 2020.
• Among the class of antibiotics prescribed, antibacterial occupy the largest market share, occupying majority (94.02%) share in the US CRBSI treatment market, followed by antifungals, which contributed USD 3.2 million in 2020.
• Among all the 7MM countries, the US accounted for the highest market size of CRBSI, which accounts for approximately 54.93% in 2020.

 

Get access to free CRBSI Sample Report: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market

 

Scope of the Catheter-Related Bloodstream Infection Market Report

• The report covers the descriptive overview of Catheter-Related Bloodstream Infection (CRBSI), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Catheter-Related Bloodstream Infection (CRBSI) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Catheter-Related Bloodstream Infection (CRBSI) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Catheter-Related Bloodstream Infection (CRBSI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Catheter-Related Bloodstream Infection (CRBSI) market

 

Catheter-Related Bloodstream Infection Therapies and Companies:

• Mino-Lok: Citius Pharmaceuticals
• Neutrolin: CorMedix
• Taurosept: Geistlich Pharma
• Taurolock: TauroPharm GmbH
• IntraLock: Fresenius Medical Care
• And Many Others

 

Get access to free CRBSI Sample Report: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Catheter-Related Bloodstream Infection (CRBSI)

3. Competitive Intelligence Analysis for Catheter-Related Bloodstream Infection (CRBSI)

4. Catheter-Related Bloodstream Infection (CRBSI): Market Overview at a Glance

5. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview

6. Patient Journey

7. Catheter-Related Bloodstream Infection (CRBSI) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Catheter-Related Bloodstream Infection (CRBSI) Treatment

11. Marketed Products

12. Emerging Therapies

13. Catheter-Related Bloodstream Infection (CRBSI): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Catheter-Related Bloodstream Infection (CRBSI)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. Publisher Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market